Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial

BACKGROUND: The high cost and insufficient supply of human papillomavirus (HPV) vaccines have slowed the pace of controlling cervical cancer. A phase III clinical trial was conducted to evaluate the efficacy, safety, and immunogenicity of a novel Escherichia coli-produced bivalent HPV-16/18 vaccine....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Natl Cancer Inst
Main Authors: Qiao, You-Lin, Wu, Ting, Li, Rong-Cheng, Hu, Yue-Mei, Wei, Li-Hui, Li, Chang-Gui, Chen, Wen, Huang, Shou-Jie, Zhao, Fang-Hui, Li, Ming-Qiang, Pan, Qin-Jing, Zhang, Xun, Li, Qing, Hong, Ying, Zhao, Chao, Zhang, Wen-Hua, Li, Yan-Ping, Chu, Kai, Li, Mei, Jiang, Yun-Fei, Li, Juan, Zhao, Hui, Lin, Zhi-Jie, Cui, Xue-Lian, Liu, Wen-Yu, Li, Cai-Hong, Guo, Dong-Ping, Ke, Li-Dong, Wu, Xin, Tang, Jie, Gao, Guo-Qi, Li, Ba-Yi, Zhao, Bin, Zheng, Feng-Xian, Dai, Cui-Hong, Guo, Meng, Zhao, Jun, Su, Ying-Ying, Wang, Jun-Zhi, Zhu, Feng-Cai, Li, Shao-Wei, Pan, Hui-Rong, Li, Yi-Min, Zhang, Jun, Xia, Ning-Shao
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7019098/
https://ncbi.nlm.nih.gov/pubmed/31086947
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djz074
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados